Hexarelin peptide is the most potent GHRP in research—studied for GH stimulation, body composition, and cardiac effects via a unique CD36 receptor. At TelosRX, peptide protocols are reviewed by licensed providers; hexarelin is not FDA-approved and subject to medical evaluation.
If you're researching growth hormone-releasing peptides, hexarelin is the outlier: it produces the largest GH pulses of any GHRP, but it also desensitizes faster and stimulates cortisol and prolactin more than its cleaner-signaling peers like ipamorelin. Understanding these tradeoffs is what separates an informed decision from a hype-driven one.
Hexarelin is not FDA-approved. It is a compounded research peptide with clinical development discontinued after Phase II trials. Here's what the actual research shows.
What Is Hexarelin?
Hexarelin (also called examorelin) is a synthetic hexapeptide developed in the 1990s as a research tool for studying growth hormone physiology. It belongs to the growth hormone-releasing peptide (GHRP) family alongside ipamorelin, GHRP-2, and GHRP-6.
Like all GHRPs, hexarelin mimics ghrelin—the hunger hormone that also signals GH release from the pituitary. Despite no structural similarity to ghrelin, hexarelin binds the same ghrelin/GH secretagogue receptor (GHSR-1a) with exceptional affinity. It activates two distinct receptor systems, which is what makes its research profile unusual even within the GHRP class.
It reached Phase II clinical trials before development was discontinued. It has never been commercially marketed as a pharmaceutical. All current clinical use is as a compounded peptide, not FDA-approved, and is only available subject to evaluation by a licensed provider.
How Hexarelin Works: Mechanism of Action
Hexarelin activates two separate receptor systems, each producing distinct physiological effects:
GHSR-1a (ghrelin receptor): Present in the pituitary and hypothalamus. Hexarelin's binding triggers phospholipase C, producing inositol trisphosphate (IP3), which increases intracellular calcium and stimulates somatotroph cells to release growth hormone. GH plasma levels typically peak within 15–20 minutes of administration. Crucially, hexarelin activates this receptor at both the pituitary (direct stimulation) and hypothalamus (stimulating endogenous GHRH release), which is why it produces larger GH pulses than GHRH alone.
CD36 (scavenger receptor): Expressed heavily in cardiac muscle, macrophages, and platelets. Hexarelin's CD36 binding is independent of GH release and accounts for the cardiovascular effects documented in preclinical research. No other widely studied GHRP has demonstrated this same CD36 interaction at comparable affinity.
This dual mechanism—GHSR-1a for GH axis effects, CD36 for cardiovascular effects—gives hexarelin a research profile that doesn't map cleanly onto any other peptide in its class.
What Research Has Found: Key Benefits
Most hexarelin research is preclinical or from early-phase human trials conducted before clinical development was discontinued. Here's what those studies actually showed:
- Superior GH release: Multiple studies confirmed hexarelin produces GH increases of 6–15x above baseline. A comparison study found hexarelin releases more GH than growth hormone-releasing hormone (GHRH) alone in healthy adult subjects.
- IGF-1 axis activation: GH elevation from hexarelin stimulates downstream IGF-1 production from the liver—a key mediator of tissue repair, protein synthesis, and growth signaling.
- Lean body composition: Animal studies showed increased lean mass and reduced fat mass with sustained GH elevation from hexarelin. Human body composition data is limited, as clinical development ended before large trials were completed.
- Synergy with GHRH analogs: When combined with GHRH or GHRH analogs like CJC-1295, hexarelin produces synergistic GH release—the two work through complementary pathways (ghrelin receptor vs GHRH receptor).
For more on how GHRP and GHRH peptides work together in combination protocols, see our research guide on the CJC-1295 and Ipamorelin growth hormone stack.
Hexarelin Cardiovascular Research: The CD36 Angle
This is where hexarelin diverges from every other GHRP in a clinically meaningful way. CD36 receptor activation produces direct cardiac effects that are independent of GH elevation—meaning they occur even when hexarelin's GH signal fades with desensitization.
A landmark study published in Circulation Research (1999) identified the CD36 receptor in cardiac tissue and showed hexarelin improved cardiac function in ischemic heart failure models. The findings included:
- Increased stroke volume and cardiac output
- Improved left ventricular ejection fraction (LVEF)
- Decreased total peripheral resistance
A 2017 PMC study confirmed hexarelin's lipid-metabolic effects in an insulin-resistant mouse model, showing improvements via CD36 pathway activation independent of GH signaling.
Important context: These are animal and preclinical findings from discontinued clinical development. Hexarelin is not approved to prevent or treat any cardiovascular condition. Human cardiovascular data is limited, and these findings do not constitute clinical claims about hexarelin's effects in people.
Hexarelin Dosage: What Research Protocols Used
Human pharmacokinetic work established a critical finding: hexarelin has a saturation threshold at approximately 2 mcg/kg body weight. Above this dose, GH release does not increase proportionally—higher doses don't produce larger GH pulses. This is different from some other GHRPs and sets a practical ceiling on dosing.
| Parameter | Research Data |
|---|---|
| Entry-level research dose | 100 mcg once or twice daily |
| Standard research dose | 200 mcg twice daily (fasted) |
| Saturation threshold | ~2 mcg/kg body weight (no further GH gain above this) |
| Time to peak GH | 15–20 minutes post-administration |
| Plasma half-life | Estimated <30 minutes (rapidly cleared) |
| Typical research cycle | 6–8 weeks on / 4–8 weeks off |
| Common administration routes | Subcutaneous injection (most studied); intranasal; IV (research only) |
The short cycle (6–8 weeks vs 8–12 weeks for GHRP-2) is deliberate and required, not optional. Hexarelin's high receptor binding affinity causes faster GHS-R1a desensitization with continuous use. Any protocol using hexarelin is subject to medical approval by a licensed provider—dosing parameters should not be self-determined.
Hexarelin Side Effects and Tolerance
Hexarelin's side effect profile is more pronounced than ipamorelin's because it's less receptor-selective. Beyond GH, it stimulates cortisol, prolactin, and ACTH—a broader hormonal signal than GHRPs designed for greater selectivity.
Side effects documented in research include:
- Water retention (edema): Most common, particularly at higher doses. GH-mediated sodium retention is the likely mechanism.
- Paresthesia (tingling): Tingling in the extremities is common to all GHRPs at meaningful doses. Usually benign and temporary.
- Fatigue: Reported in early weeks, often decreasing over time.
- Elevated cortisol and prolactin: More pronounced with hexarelin than with ipamorelin or GHRP-6. Clinically relevant if sustained over long cycles.
- Appetite stimulation: Ghrelin receptor activation inherently signals hunger. Common across GHRPs; typically mild.
- Headache: Reported in some users, likely related to GH spike and fluid shifts.
Hexarelin does not appear to significantly affect glucose, LH, FSH, or TSH at research doses—making it relatively selective within the GH/cortisol/prolactin axis.
Desensitization: Studies—including a key pharmacokinetic analysis—document a 50–75% decline in GH response with prolonged continuous use. This is the primary clinical limitation and the reason research protocols mandate off-cycles. Receptor sensitivity typically recovers during the off period.
Hexarelin vs Ipamorelin: Key Differences
| Feature | Hexarelin | Ipamorelin |
|---|---|---|
| GH release potency | Very high (strongest GHRP) | Moderate |
| Receptor selectivity | Low — also stimulates cortisol, prolactin, ACTH | High — minimal cortisol/prolactin effect |
| Desensitization rate | Rapid (6–8 week cycles required) | Slower (8–12 week cycles typical) |
| Cardiovascular research (CD36) | Yes — documented in preclinical models | Limited |
| Clinical development stage | Phase II — discontinued | Phase II — discontinued |
| Side effect burden | Higher (cortisol, prolactin, water retention) | Lower — cleaner hormonal profile |
| FDA approval status | Not FDA-approved | Not FDA-approved |
Ipamorelin is generally preferred in clinical peptide research for its cleaner hormonal signal. Hexarelin's niche is where maximum GH stimulation is the priority—or where its CD36 cardiovascular research angle is specifically relevant to the research question.
For a different approach to GH support, see our overview of sermorelin, a GHRH analog that works through a completely different receptor pathway and has a distinct clinical profile. Also relevant: the relationship between growth hormone axis support and broader longevity goals, covered in our NAD+ therapy overview.
Getting Evaluated for Peptide Protocols at TelosRX
TelosRX reviews peptide protocols through its asynchronous telehealth platform. Hexarelin, as a compounded peptide that is not FDA-approved, is reviewed on a case-by-case basis. Not all requests result in a prescription—approval depends on clinical history, goals, and provider judgment.
The evaluation intake covers your health history, current medications, prior peptide experience, and research goals—giving providers the clinical context to assess which compounds, if any, may be appropriate. See also our overview of testosterone optimization for related hormone support approaches.
Frequently Asked Questions
What is hexarelin peptide used for?
Hexarelin has been studied for growth hormone stimulation, body composition research, and cardiovascular function via CD36 receptor binding. It is not FDA-approved for any indication. All current use is as a compounded peptide not FDA-approved, available only through evaluation by a licensed provider. Research applications remain primarily in growth hormone physiology.
Is hexarelin stronger than ipamorelin?
In terms of raw GH release, yes—hexarelin is the most potent GHRP, producing larger GH pulses than ipamorelin at comparable doses. However, hexarelin is far less selective: it also stimulates cortisol and prolactin, which ipamorelin largely avoids. Whether "more potent" equals "better" depends heavily on the specific research context and individual tolerance.
What are the side effects of hexarelin?
Common research-documented side effects include water retention, tingling (paresthesia), fatigue, elevated cortisol and prolactin, appetite stimulation, and headache. Hexarelin raises cortisol and prolactin more than most other GHRPs. Side effects are typically dose-dependent and often managed through appropriate dose selection and cycling protocols determined by a licensed provider.
How do you dose hexarelin?
Research protocols have used 100–200 mcg once or twice daily, administered subcutaneously in a fasted state. A saturation effect occurs at approximately 2 mcg/kg body weight, so higher doses don't proportionally increase GH output. All dosing parameters for clinical protocols must be determined and approved by a licensed provider. Self-dosing compounded peptides outside provider oversight is not appropriate.
Does hexarelin cause desensitization?
Yes, more rapidly than most other GHRPs. Hexarelin's high receptor binding affinity causes faster GHS-R1a desensitization, with studies documenting a 50–75% decline in GH response with prolonged continuous use. Research protocols use 6–8 week cycles followed by 4–8 week off-periods to allow receptor recovery. Continuous administration without breaks substantially reduces efficacy.
What is the half-life of hexarelin?
Hexarelin's plasma half-life is short—estimated at under 30 minutes for most routes of administration. GH peaks within 15–20 minutes of injection and returns toward baseline within a few hours. This rapid clearance is characteristic of synthetic peptides and is why multiple daily dosing is used in research protocols rather than single daily administration.
Is hexarelin FDA-approved?
No. Hexarelin is not FDA-approved for any indication. Clinical development was discontinued after Phase II trials and it was never commercially marketed as a pharmaceutical. It is only available as a compounded peptide, not FDA-approved, and any use requires a prescription issued by a licensed provider following an appropriate evaluation.
Can hexarelin support cardiovascular health?
Preclinical research—including animal models of heart failure—showed hexarelin improving cardiac output, stroke volume, and left ventricular ejection fraction through CD36 receptor activation. These are animal and early preclinical findings. Hexarelin is not approved to treat or prevent any cardiovascular condition. These research findings cannot be extrapolated as clinical claims for human outcomes.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.